Clinical Trials Directory

Trials / Conditions / Anaplastic Large Cell Lymphoma, ALK-Positive

Anaplastic Large Cell Lymphoma, ALK-Positive

14 registered clinical trials studyying Anaplastic Large Cell Lymphoma, ALK-Positive — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingConstitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
NCT06176690
Baylor College of MedicinePhase 1
Active Not RecruitingChemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
NCT07013565
New York Medical CollegePhase 2
RecruitingA Registry for People With T-cell Lymphoma
NCT05978141
Memorial Sloan Kettering Cancer Center—
RecruitingBrigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
NCT04925609
Princess Maxima Center for Pediatric OncologyPhase 1 / Phase 2
WithdrawnBrigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
NCT03719898
Fox Chase Cancer CenterPhase 2
CompletedProspective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma
NCT03603847
The Lymphoma Academic Research Organisation—
CompletedStudy of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451
BeiGenePhase 2
WithdrawnCeritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
NCT02729961
University of WashingtonPhase 1 / Phase 2
UnknownA Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
NCT03505554
University of Milano BicoccaPhase 2
Active Not RecruitingTalimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor
NCT02978625
National Cancer Institute (NCI)Phase 2
Active Not RecruitingBrentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lym
NCT03113500
City of Hope Medical CenterPhase 2
CompletedCombination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphom
NCT02561273
University of NebraskaPhase 1 / Phase 2
CompletedPilot Study of Crizotinib in Relapsed ALK+ Lymphomas
NCT02419287
University of Milano BicoccaPhase 2
CompletedBrentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage
NCT01979536
National Cancer Institute (NCI)Phase 2